Active in the sectors: Bio/Life Sciences Type of organisation: Multinational Number of employees: 2074 Number of locations: 10 + General argenx is the global immunology innovation company, focused on turning immunology breakthroughs into medicines for patients who need them most. The company seeks novel biology wherever it emerges, co-creating with academic researchers through its Immunology Innovation Program (IIP) and investing in promising science, to develop treatments for people living with underserved diseases. By advancing molecules with the potential to reach multiple diseases and patient populations, argenx is building a world-class portfolio. This approach produced the first approved antibody fragment targeting the neonatal Fc receptor (FcRn) and today powers a growing pipeline of late-stage and pre-clinical programs across several therapeutic areas.